Loading clinical trials...
Loading clinical trials...
There are limited but encouraging results supporting the use of dalfampridine in patients with hereditary spastic paraplegia. The investigators aimed to investigate the effects of dalfampridine on wal...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
European University of Lefke
NCT07136844 · Neuromuscular Diseases, Obesity (Disorder), and more
NCT06844734 · Hereditary Spastic Paraplegia
NCT06742697 · Hereditary Spastic Paraplegia
NCT03981276 · Hereditary Spastic Paraplegia
NCT01568658 · Muscular Dystrophies, Muscle Myopathies, and more
Dr. Burhan Nalbantoğlu State Hospital
Nicosia
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions